Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of long-term gantenerumab
2020-000766-42Phase 3Unknown
- Sponsor
- Roche
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Safety and tolerability of long-term gantenerumab. Status: unknown.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-000766-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000766-42.